RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
← catalyst calendarSponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →. With Roche Pharma AG.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
5actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business reasons.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-29 | actual | When the study began enrolling |
| Primary completion | 2025-08-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-18 | actual | The whole study's end, after follow-up |
| First posted | 2023-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Refractory Metastatic Colorectal Cancer
- pMMR
- MSS
Interventions
- Biological: RP2
- Biological: RP3
- Biological: atezolizumab
- Biological: bevacizumab
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured From Day 1 to documented progression of disease (up to 3 years)
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed